1. Home
  2. KPTI vs STG Comparison

KPTI vs STG Comparison

Compare KPTI & STG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • KPTI
  • STG
  • Stock Information
  • Founded
  • KPTI 2008
  • STG 2003
  • Country
  • KPTI United States
  • STG China
  • Employees
  • KPTI N/A
  • STG N/A
  • Industry
  • KPTI Biotechnology: Pharmaceutical Preparations
  • STG Other Consumer Services
  • Sector
  • KPTI Health Care
  • STG Real Estate
  • Exchange
  • KPTI Nasdaq
  • STG Nasdaq
  • Market Cap
  • KPTI 81.1M
  • STG 91.6M
  • IPO Year
  • KPTI 2013
  • STG 2018
  • Fundamental
  • Price
  • KPTI $0.59
  • STG $6.78
  • Analyst Decision
  • KPTI Strong Buy
  • STG
  • Analyst Count
  • KPTI 4
  • STG 0
  • Target Price
  • KPTI $5.00
  • STG N/A
  • AVG Volume (30 Days)
  • KPTI 698.5K
  • STG 9.1K
  • Earning Date
  • KPTI 02-19-2025
  • STG 03-21-2025
  • Dividend Yield
  • KPTI N/A
  • STG N/A
  • EPS Growth
  • KPTI N/A
  • STG N/A
  • EPS
  • KPTI N/A
  • STG 4.57
  • Revenue
  • KPTI $148,442,000.00
  • STG $292,030,936.00
  • Revenue This Year
  • KPTI $4.47
  • STG N/A
  • Revenue Next Year
  • KPTI $7.35
  • STG N/A
  • P/E Ratio
  • KPTI N/A
  • STG $1.46
  • Revenue Growth
  • KPTI 1.77
  • STG N/A
  • 52 Week Low
  • KPTI $0.58
  • STG $4.25
  • 52 Week High
  • KPTI $1.70
  • STG $12.55
  • Technical
  • Relative Strength Index (RSI)
  • KPTI 37.30
  • STG 55.98
  • Support Level
  • KPTI $0.60
  • STG $6.51
  • Resistance Level
  • KPTI $0.67
  • STG $6.92
  • Average True Range (ATR)
  • KPTI 0.05
  • STG 0.20
  • MACD
  • KPTI -0.00
  • STG 0.02
  • Stochastic Oscillator
  • KPTI 4.16
  • STG 60.09

About KPTI Karyopharm Therapeutics Inc.

Karyopharm Therapeutics Inc is a commercial-stage pharmaceutical company pioneering novel cancer therapies and dedicated to the discovery, development, and commercialization of drugs directed against nuclear export for the treatment of cancer and other diseases. XPOVIO (selinexor), is approved in the U.S. in multiple hematologic malignancy indications, including in combination with Velcade (bortezomib) and dexamethasone for the treatment of adult patients with multiple myeloma after at least one prior therapy, in combination with dexamethasone for the treatment of adult patients with heavily pretreated multiple myeloma and as a monotherapy for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma. The company derives its revenue from United States.

About STG Sunlands Technology Group

Sunlands Technology Group is a provider of online post-secondary and professional education services in China. The company offers various degree- and diploma-oriented post-secondary courses through its online platforms. In addition, it provides online professional courses and educational content to help students prepare for professional certification exams and attain professional skills. The Group has one operating segment, which is the provision of online education services.

Share on Social Networks: